EPO Patents = 3

Forward Citations = 1

Loading Chart...

9 inventors (with patents filed for the assignee):

Alfredo Nicosia (5 out of 28 patents)

Armin Lahm (4 out of 19 patents)

Elisa Scarselli (3 out of 4 patents)

4. Stefano Colloca (2 out of 28 patents)

5. Guido Leoni (2 out of 3 patents)

6. Alfredo Nicosia (1 out of 1 patent)

7. Elisa Scarselli (1 out of 1 patent)

8. Armin Lahm (1 out of 1 patent)

9. Antonella Folgori (1 out of 1 patent)

10. Maria Gabriella Campadelli (4 patents)

6 patents: Sort by Forward Citations

1. 12749556 - SELECTION OF CANCER MUTATIONS FOR GENERATION OF A PERSONALIZED CANCER VACCINE (2026-09-29),

2. 12576143 - TELEOST INVARIANT CHAIN CANCER VACCINE (2026-03-17),

3. 11912743 - Compositition and uses of teleost invariant chain to enhance T cell response to a vaccine (2024-02-27),

4. 11643666 - Eukaryotic cell line (2023-05-09),

5. 11578109 - Universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers (2023-02-14),

6. 11098324 - Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof (2021-08-24),

Nouscom is a biotechnology company focused on the development of personalized cancer immunotherapies. The company is dedicated to harnessing the power of the immune system to target and eradicate cancer cells. Nouscom's innovative approach combines cutting-edge technologies with deep scientific expertise to create novel immunotherapies that have the potential to transform cancer treatment. With a strong pipeline of promising candidates, Nouscom aims to make a significant impact in the fight against cancer.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

6 Patents

#54 in Basel

#1,479 in Switzerland

Basel, Switzerland

Nouscom Ag